Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Follow-up After Metastasectomy in Patients With Kidney Cancer

Active, not recruiting

Conditions: Renal Cell Carcinoma

Interventions: Other: Follow-Up Care
Other: Laboratory Biomarker Analysis

First Posted Date: 2009-06-11

Last Posted Date: 2025-04-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 86

Registration Number: NCT00918775

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Xeloda (Capecitabine) and External Beam Radiation

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Radiation: Radiation Therapy
Drug: Capecitabine

First Posted Date: 2009-06-09

Last Posted Date: 2018-07-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 33

Registration Number: NCT00916578

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence

Phase 2

Completed

Conditions: Non-Small-Cell Lung Carcinoma

Interventions: Radiation: Proton Therapy
Radiation: Photon Therapy
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2009-06-05

Last Posted Date: 2020-05-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 275

Registration Number: NCT00915005

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Sunitinib Malate in Refractory Germ Cell Tumors

Phase 2

Terminated

Conditions: Genitourinary Disease

Interventions: Drug: Sunitinib Malate

First Posted Date: 2009-06-03

Last Posted Date: 2016-04-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5

Registration Number: NCT00912912

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Patient-Reported Outcomes Version of Common Terminology Criteria (CTCPRO) Cognitive Debriefing

Completed

Conditions: Advanced Cancers
Hematologic Diseases
Solid Tumors

Interventions: Behavioral: Interview

First Posted Date: 2009-05-27

Last Posted Date: 2014-07-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT00909207

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

and more 1 locations

Self Reported Deviations From Opioid Analgesic Prescription

Completed

Conditions: Advanced Cancers

Interventions: Behavioral: Personal Interview
Behavioral: Questionnaire

First Posted Date: 2009-05-22

Last Posted Date: 2013-06-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 201

Registration Number: NCT00907192

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Beta Glucan Assay in Patients Receiving Voriconazole Prophylaxis

Phase 3

Completed

Conditions: Leukemia
Fungal Infection

Interventions: Drug: Voriconazole

First Posted Date: 2009-05-20

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 23

Registration Number: NCT00904995

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage

Phase 2

Completed

Conditions: Leukemia, Lymphocytic, Acute

Interventions: Drug: Methotrexate
Drug: Vincristine
Drug: PEG-l-asparaginase
Drug: Dexamethasone
Drug: Rituximab

First Posted Date: 2009-05-20

Last Posted Date: 2015-06-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 37

Registration Number: NCT00905034

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: CT-011
Drug: Rituximab

First Posted Date: 2009-05-20

Last Posted Date: 2016-06-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 32

Registration Number: NCT00904722

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)

Phase 2

Completed

Conditions: Myelodysplastic Syndrome

Interventions: Drug: Decitabine
Drug: Clofarabine

First Posted Date: 2009-05-18

Last Posted Date: 2018-11-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 42

Registration Number: NCT00903760

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy